Clinical trial

A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

NCT07189325

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-06-15

PhasePHASE3

Study timeline

Study start (actual)2026-06-15Date precision: day

Registry last updated2026-06-23

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Relapsing-Remitting Multiple Sclerosis (RRMS)unresolved

Anti-CD20 Therapyunresolved

Interventions

Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons)DRUG

Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab)DRUG

Sponsors & collaborators

University Hospital, Montpellierlead sponsor

Mapped research locations

MontpellierFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07189325 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.